輸入代號或公司名稱後按 Enter
ACAD

ACADIA PHARMACEUTICALS INC

+0.02 (+0.07%)前一交易日收盤 2026-09-17
美股 · Nasdaq · 生技醫療 · Pharmaceutical Preparations
27.56USD465K成交股數4.7B市值12.4本益比(近四季)4.2股價營收比+16.4%營收年增(近四季)2026-11-04下次財報

財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束

逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。

營收與利潤率近 16 季

稀釋 EPS近 16 季 · 美元

現金流近 16 季

股東回饋近 16 季 · 庫藏股與股利

損益表 逐季 · 最新在左 · 小字是年增率

科目26Q226Q125Q425Q325Q225Q124Q324Q224Q123Q423Q323Q2
營收308M+16%268M+10%284M+13%279M+15%265M+29%244M+6%250M+18%242M+46%206M231M212M165M
營業成本28.3M24.8M26.2M21.6M20.7M20.4M18.9M18.2M23.0M14.6M7.5M
毛利280M+15%243M+9%258M+11%257M+15%244M+33%224M+5%232M+17%224M+42%183M213M197M158M
毛利率90.8%90.8%90.8%92.2%92.2%91.7%92.5%92.5%88.8%92.3%93.1%95.5%
研發費用81.6M76.9M84.8M87.8M78.0M78.3M66.6M76.2M59.7M157M58.8M
銷售管理費用160M171M156M133M134M126M133M117M108M97.9M96.0M
營業利益37.8M+17%−4.6M-124%17.4M-45%35.8M+17%32.4M+113%19.3M31.6M-155%30.4M+902%15.2M−57.8M3.0M
營業利益率12.3%-1.7%6.1%12.8%12.2%7.9%12.6%12.6%7.4%-27.3%1.8%
稅後淨利31.5M+18%3.6M-81%274M+735%71.8M+115%26.7M+61%19.0M-59%32.8M-150%33.4M+2897%16.6M45.8M−65.2M1.1M
淨利率10.2%1.4%96.3%25.8%10.1%7.8%13.1%13.8%8.0%19.8%-30.8%0.7%
稀釋 EPS0.18+13%0.02-82%1.61+705%0.42+110%0.16+60%0.11-61%0.20-150%0.20+1900%0.100.28-0.400.01
稀釋股數173M173M170M171M169M168M166M166M167M164M165M

資產負債表 期末餘額

科目26Q226Q125Q425Q325Q225Q124Q324Q224Q123Q423Q323Q2
現金與約當現金385M282M178M258M254M218M155M177M205M189M98.2M108M
應收帳款151M135M121M116M108M106M98.2M104M94.7M98.3M92.8M81.9M
存貨109M112M111M106M111M103M86.7M86.1M66.6M40.4M25.4M14.1M
總資產1.7B1.6B1.6B1.3B1.2B1.1B977M914M855M749M633M643M
有息負債
總負債436M357M337M413M403M367M400M397M391M317M270M247M
股東權益1.3B1.2B1.2B917M822M765M577M517M464M432M362M396M
負債比25.0%22.3%21.5%31.1%32.9%32.4%40.9%43.5%45.7%42.4%42.7%38.4%
淨現金(現金 − 有息負債)

現金流量表 單季

科目26Q226Q125Q425Q325Q225Q124Q324Q224Q123Q423Q323Q2
營業現金流34.0M+67%20.3M29.1M
資本支出5.2M0.00
自由現金流28.8M+42%20.3M
折舊攤銷
買回庫藏股
現金股利
自由現金流率10.7%8.3%

營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度

業務分部2025 年度 · 1.1B
Reportable Segment Aggregation Before Other Operating1.1B100.0%+11.9%
主要客戶2025 年度 · 1.1B
Nuplazid680M63.5%+11.6%
Daybue391M36.5%+12.3%

各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。

年度 10-K

財年營收年增稅後淨利淨利率稀釋 EPS自由現金流
FY20251.1B+11.9%391M36.5%2.30105M
FY2024958M+31.8%226M23.6%1.36157M
FY2023726M+40.4%−61.0M-8.4%-0.3716.7M
FY2022517M+6.8%−214M-41.4%-1.34−114M
FY2021484M+9.6%−168M-34.7%-1.05−127M
FY2020442M+30.3%−282M-63.7%-1.79−144M
FY2019339M+51.5%−235M-69.4%-1.60−152M
FY2018224M−245M-109.6%-1.94−170M